MedTrace Logo

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

NCT02832063 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2022-09-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.

Conditions

  • Acne Vulgaris

Interventions

BIOLOGICAL

B244

4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

BIOLOGICAL

Placebo

4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.

Sponsors & Collaborators

  • AOBiome LLC

    lead INDUSTRY

Principal Investigators

  • Noah Craft, MD · Science 37

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-07-19
Completion
2017-07-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832063 on ClinicalTrials.gov